HighTower Advisors LLC Has $1.56 Million Position in Certara, Inc. (NASDAQ:CERT)

HighTower Advisors LLC boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 647.2% during the fourth quarter, Holdings Channel reports. The fund owned 146,539 shares of the company’s stock after acquiring an additional 126,927 shares during the period. HighTower Advisors LLC’s holdings in Certara were worth $1,561,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CERT. Brown Brothers Harriman & Co. acquired a new position in shares of Certara during the third quarter worth approximately $27,292,000. Wasatch Advisors LP boosted its position in Certara by 22.4% in the 3rd quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Certara by 169.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after buying an additional 1,253,385 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 40.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after buying an additional 1,128,006 shares during the period. Finally, Glenmede Trust Co. NA raised its position in shares of Certara by 78.6% during the third quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after acquiring an additional 530,598 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Up 0.5 %

Shares of NASDAQ CERT opened at $10.78 on Tuesday. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.18. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -53.90, a P/E/G ratio of 9.29 and a beta of 1.60. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average is $12.54 and its 200-day moving average is $11.48.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CERT. Barclays raised their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. TD Cowen began coverage on shares of Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price for the company. Stephens reiterated an “overweight” rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Finally, William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Certara has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.